Blueprint Medicines

BLUEPRINT MEDICINES CORP

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Usa,America,Trade,War,Economy,Conflict,Tax,Business,Finance, - 

News

Initiation

Markets

Analyst Ratings

AXGN

BFLY

BPMC

EZPW

PSNL

This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Quantum Computing

Equities

Mid Cap

Movers

Trading Ideas

ALHC

COMP

HEES

IBRX

IONQ

MSFT

NVDA

OPCH

SEMR

Explore this week&#39;s top-performing mid-cap stocks, including H&amp;E Equipment Services&#39; impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush and Blueprint Medicines also experienced significant gains, impacting investment portfolios positively.

IonQ, H&amp;E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

movers image

Intraday Update

BIIB

CRML

ITCI

RADX

SAGE

SIBN

Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines Corp

Earnings

Press Releases

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

ADMA Biologics

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Genmab

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Nuvalent

Vaxcyte

PTC Therapeutics

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Soleno Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

HC Wainwright & Co.

Needham

Wedbush

Morgan Stanley

Jefferies

Comments

Blueprint Medicines

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell